Read More Pharma Industry News Affimed N.V. reports promising results from AFM24-102 trial in NSCLC Affimed N.V. (Nasdaq: AFMD), a pioneering immuno-oncology company, has released compelling clinical data from its ongoing AFM24-102 study,… byPallavi MadhirajuJune 4, 2024